Your browser doesn't support javascript.
loading
[Retinal drug targets]. / Cibles rétiniennes d'action des médicaments.
Behar-Cohen, F.
Afiliação
  • Behar-Cohen F; Inserm UMRS, Équipe physiopathologie oculaire : innovations thérapeutiques, centre de recherches des Cordeliers, Hôtel-dieu, université Paris-Descartes, France. francine.behar-cohen@crc.jussieu.fr
Ann Pharm Fr ; 69(2): 124-30, 2011 Mar.
Article em Fr | MEDLINE | ID: mdl-21440105
ABSTRACT
Retinal effects of systemically administered drugs are rare due to the hematoretinal barriers that protect the retina from circulating active principles. However, some compounds may have direct or indirect toxic effects on the retina through direct interaction with a specific receptor or due to their accumulation within pigment of uveal cells. In the latter case, toxicity is dose-dependent and may be observed years after cessation of medication, as observed with antimalarial drugs. Anti-infective and anti-inflammatory agents, particularly glucocorticoids, are currently injected peri- or intraocularly. The mechanisms and the exact toxicity of glucocorticoids on the retina remain poorly understood. More recently, anti-VEGF has been specifically developed for the treatment of retinal diseases. However, the long-term blockade of VEGF on normal retinal physiology should be determined taking into account VEGF and VEGF receptors expression in the normal and pathologic retina. Whilst enormous advances are made in the treatment of retinal diseases, basic research is still required to define more accurately the molecular targets of drugs to improve their benefits and reduce their potential side effects.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Retina / Doenças Retinianas Limite: Animals / Humans Idioma: Fr Ano de publicação: 2011 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Retina / Doenças Retinianas Limite: Animals / Humans Idioma: Fr Ano de publicação: 2011 Tipo de documento: Article